YU8896A - Use of alendronate for preparation a medicament for lessening the risk of vetebral and nonvetebral fractures - Google Patents

Use of alendronate for preparation a medicament for lessening the risk of vetebral and nonvetebral fractures

Info

Publication number
YU8896A
YU8896A YU8896A YU8896A YU8896A YU 8896 A YU8896 A YU 8896A YU 8896 A YU8896 A YU 8896A YU 8896 A YU8896 A YU 8896A YU 8896 A YU8896 A YU 8896A
Authority
YU
Yugoslavia
Prior art keywords
alendronate
fractures
nonvetebral
vetebral
lessening
Prior art date
Application number
YU8896A
Other languages
Serbo-Croatian (sh)
Inventor
A. David Karpf
P. Thomas Capizzi
Quan Hui
C. Arthur Santora
J. Ashley Yates
J. William Polvino
R. Deborah Shapiro
E. Desmond Thompson
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU8896(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/389,860 external-priority patent/US20010051616A1/en
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of YU8896A publication Critical patent/YU8896A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Alendronat, jedan bisfosfonat, kada se primenjuje svakodnevno u toku bitnog perioda vremena, može da smanji razmeru kičmenih i ne-kičmenih preloma kod žena posle menopauze. Dalje, on može da smanji broj i ozbiljnost preloma. Isto tako, primena alendronata može da spreči deformitet kičme, i gubitak u visini.Alendronate, a single bisphosphonate, when administered daily over a significant period of time, can reduce the proportion of spinal and non-spinal fractures in post-menopausal women. Furthermore, it can reduce the number and severity of fractures. Likewise, administration of alendronate can prevent spinal deformity and height loss.

YU8896A 1995-02-17 1996-02-16 Use of alendronate for preparation a medicament for lessening the risk of vetebral and nonvetebral fractures YU8896A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39046295A 1995-02-17 1995-02-17
US08/389,860 US20010051616A1 (en) 1995-02-17 1995-02-17 Method of lessening the risk of vertebral fractures
US41963195A 1995-04-10 1995-04-10

Publications (1)

Publication Number Publication Date
YU8896A true YU8896A (en) 1999-12-27

Family

ID=27409915

Family Applications (1)

Application Number Title Priority Date Filing Date
YU8896A YU8896A (en) 1995-02-17 1996-02-16 Use of alendronate for preparation a medicament for lessening the risk of vetebral and nonvetebral fractures

Country Status (9)

Country Link
AR (1) AR002707A1 (en)
CO (1) CO4920257A1 (en)
CZ (1) CZ259097A3 (en)
DZ (1) DZ1991A1 (en)
HR (1) HRP960080A2 (en)
IL (1) IL117077A (en)
PE (1) PE46197A1 (en)
TW (1) TW453880B (en)
YU (1) YU8896A (en)

Also Published As

Publication number Publication date
TW453880B (en) 2001-09-11
IL117077A (en) 2002-08-14
PE46197A1 (en) 1997-11-28
CO4920257A1 (en) 2000-05-29
DZ1991A1 (en) 2002-07-20
CZ259097A3 (en) 1997-11-12
AR002707A1 (en) 1998-04-29
IL117077A0 (en) 1996-06-18
HRP960080A2 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
PL299814A1 (en) Pharmaceutical preparation inhibiting depletion of human bone tissue
MY112915A (en) Multiple unit tableted dosage form 1
FR2720002B1 (en) Incision device for the dermal administration of a medicament.
NO20053105D0 (en) Oral, extended-release analgesic dosage form for administration ± once per day. day.
ZA967502B (en) Medicament delivery device.
TW272940B (en) /
GEP20063773B (en) Steroid Sulphatase Inhibitors
EP0745401A3 (en) Inhaler type medicine administering device
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
AU2711295A (en) Combination treatment for inhibiting bone loss
DE59510333D1 (en) PHARMACEUTICAL COMBINATION FOR HORMONAL CONTRACTION
AU3225993A (en) Patient controlled bolus dosage infuser
WO1999004772A3 (en) Use of levobupivacaine
EP0744176A3 (en) Methods for inhibiting bone loss
GB9114493D0 (en) Drug delivery system for administering growth factors
YU8896A (en) Use of alendronate for preparation a medicament for lessening the risk of vetebral and nonvetebral fractures
AR059965A2 (en) USE OF 8,9-DEHYDROESTRONE FOR THE PREPARATION OF AN ANTIOXIDANT MEDICINAL PRODUCT
DE69616591D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING MUIRAPUAMA AND PLANT WORMS
AU2691197A (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
SI0711163T1 (en) Use of benzydamine in the treatment of pathological conditions caused by tnf
NO981320L (en) Oral use of (+) - O-demethyltramadol as a pain reliever
MX9706275A (en) Method of lessening the risk of vertebral fractures.
UA30722A (en) Method for prophylaxis of festering-septic complications in parturient women
ITTO920146A1 (en) MEDICAL PACKAGE FOR UROLOGICAL INTERVENTION.